—
DescriptionPersonalized Medicine. Targeted Therapeutics and Companion Diagnostic Market- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment to 2021” (published May 2017)
Research forecasts that the companion diagnostic and targeted therapeutic submarkets of the personalized medicine industry were worth $113 billion in 2016, and will hit over $162 billion by 2021 with a CAGR of 8.74%. The total personalised therapeutic market, for all indications, will be worth $x billion by 2021, with a CAGR of x%. Currently it is estimated that the companion diagnostic segment is worth $x billion globally, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. This is set to rise vertically over the next five years and by 2021 will be worth over $x billion, with a CAGR of x%.
GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/1309114-personalized-medicine-targeted-therapeutics-companion-diagnostic-market-to-2021
Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies.
Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics are more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine reduces the frequency of adverse drug reactions and therefore has a dramatic impact on health economics. Developmental and diagnostic companies benefit from lower discovery and commercialization costs and more specific market subtypes.
This new report gives a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine market is presented as follows:
By Company (e.g., QIAGEN, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)
By Segment (Targeted therapeutics, Companion Diagnostics)
By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy)
By Therapy (Cancer, Cardiovascular, Infectious Disease)
Key Opinion Leaders that contributed to interview questions within the report include:
Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group
Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James’s Hospital and Trinity College Dublin, Ireland
Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC
Elaine Kenny, PhD, Founder, Elda Biotech, Dublin, Ireland
Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine
Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine
David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine
Deborah Phippard, PhD, Vice President, Research, Precision for Medicine
Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine
A wealth of financial data & business strategy information is provided including:
Company Financials, Sales & Revenue Figures
Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies
Business Model Strategies for Providers. Provider Systems and Academic Medical Centres
Business Model Strategies for Payers & Governments
Private and Public Funding and Personalized Medicine Reimbursement
Revisions to Current Payment Systems and Intellectual Property
How to Gain Market Penetration in the EU
Cost-effectiveness and Business Value of Personalized Medicine
Consumer genomics and POC market
Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
Comprehensive Account of Company Product Portfolios & Kits
SWOT, Economic & Regulatory Environment specifics include:
Key Strengths, Weaknesses and Threats Influencing Leading Player Position within the Market
Technologies Driving the Market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
Top Fastest Growing Market Segments and Emerging Opportunities
Top Pharmaceutical Companies within the IPM by Market Share and Revenue
Comprehensive Product Portfolios, R&D Activity and Pipeline Therapeutics
M&A Activity and Future Strategies of Top Personalized Medicine Pharmacos
Personalized Medicine Regulation (UK, Germany, France, Spain, Italy)
CE-Marked Personalized Medicine/Diagnostic Tests
FDA Advances in Personalized Medicine Regulation
This report highlights a number of significant players and influential company’s and gives details of their operations, products, financials and business strategy.
23andMe
Abbott Laboratories
Abbott Molecular Inc.
Admera Health (GENEWIZ)
Affymetrix
Agendia
Alere
Amgen
Astex Pharmaceuticals
AstraZeneca
Atossa Genetics
Becton Dickenson
bioMerieux
BristolMyersSquibb
Cancer Genetics
Celera (Quest Diagnostics)
Celldex Therapeutics
Claritas Genomics
CuraGen
Danaher (Leica Biosystems)
deCode Genetics (Amgen)
Foundation Medicine
EDP Biotech
Eli Lilly
ELDA BioTech
Eisai
Genelex
GlaxoSmithKline
Human Longevity Inc (Cypher Genomics)
HalioDx
Ikonisys
Illumina
InterGenetics
Johnson & Johnson
LabCorp
Life Technologies
Merck
MDxHealth
MolecularMD Corporation
Monogram Biosciences
Myriad
Nodality
Novartis MDx
Orion Genomics
Oxford BioTherapeutics
NanoString Technologies
Pfizer
Qiagen
Updates on the personalized medicine, targeted therapeutic and companion diagnostic space have been included in this latest edition to include cutting edge material from international conferences, workshops and symposia.
Who should read this report?
Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
Industry professionals and business strategists will discover key information to propel their policies
Investors will gain inside information to dominant players in the industry and future forecasts
Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment
This report will tell you if the companies mentioned are:
Strong, competitive players
Pooling their resources for specific growth and therapeutic areas
Investing strategically in R&D
Have a history of strategic M&A activity
This detailed report is supported with over 365 tables & figures over 397 pages and profiles the main pharmacos in personalized medicine.
Table of Content: Key Points
Executive Summary
1.1 Objectives of Report
1.2 Scope of Study
1.3 Data Sources and Methodology
1.4 Key Findings and Observations
1.4.1 CYP2C9 and VKORC1 mutations and Warfarin Response
1.4.2 KRAS Mutations
1.4.3 Herceptin® and Breast Cancer
1.4.4 BRACAnalysis®
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/1309114-personalized-medicine-targeted-therapeutics-companion-diagnostic-market-to-2021
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +44 208 133 9349
Website: http://www.wiseguyreports.com
Release ID: 206967